# Sanofi Ventures

> Sanofi Ventures is a VC fund backing Biotechnology and Health Care. See 122 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 122
- Last investment: Aug 2026
- Lead investor: 26%
- Fund size: $750M
- Last fund: Dec 2001
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sanofi-ventures
- Website: http://sanofiventures.com

Sanofi Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potentialcures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.

## Contacts

5 contacts available for Sanofi Ventures. Shizune tracks 9 team members at Sanofi Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sanofi-genzyme-bioventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $9M–$140M |
| Series B | $30M–$125M |
| Series C | $30M–$120M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 57 | 47% |
| Health Care | 43 | 35% |
| Medical | 30 | 25% |
| Therapeutics | 26 | 21% |
| Pharmaceutical | 22 | 18% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 38 | 31% |
| Series A | 29 | 24% |
| Series C | 15 | 12% |
| Seed | 8 | 7% |
| Funding Round | 5 | 4% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 58 | 48% |
| United Kingdom | 4 | 3% |
| France | 2 | 2% |
| Israel | 2 | 2% |
| Denmark | 2 | 2% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christopher Gagliardi | Principal | 10 | https://shizune.co/investors/profile/christopher-gagliardi |
| Alan Walts | Managing Director | 2 | https://shizune.co/investors/profile/alan-walts-d3ea |
| Alba Zurriaga Carda | Director of Investments | 0 | https://shizune.co/investors/profile/alba-zurriaga-carda |
| Charles Thyne | Industrial Operations | 0 | https://shizune.co/investors/profile/charles-thyne |
| Cris De Luca | Partner, Digital Investments, Sanofi Ventures | 7 | https://shizune.co/investors/profile/cris-de-luca |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| QuantHealth | Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services. | $45M | Series B | Aug 04, 2026 |  |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M | Series D | Jul 15, 2026 |  |
| Nura Bio | Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M | Series B | Jun 22, 2026 |  |
| Bionyra | Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M | Series A | Jun 22, 2026 |  |
| Memento Medicines | Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M | Series A | Jun 18, 2026 |  |
| BranchLab | BranchLab makes healthcare advertising better so that people may find the best healthcare options. | $28.8M | Series A | May 13, 2026 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| QuantX Biosciences | QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $85M | Series B | Feb 09, 2026 |  |
| QuantX Biosciences | QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $85M | Series B | Feb 09, 2026 |  |

10 of 122 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 20 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 12 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 12 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 11 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 11 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 11 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Medical VC Funds](https://shizune.co/investors/medical-vc-funds)
- [Medical Investors](https://shizune.co/investors/medical-investors)
- [Medical VC Funds in United States](https://shizune.co/investors/medical-vc-funds-united-states)
- [Medical VC Funds in Denmark](https://shizune.co/investors/medical-vc-funds-denmark)

## FAQ

### What does Sanofi Ventures invest in?

Sanofi Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 122 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sanofi Ventures's check size?

Sanofi Ventures typically joins rounds of $9M–$140M at Series A, $30M–$125M at Series B and $30M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sanofi Ventures participates in.

### How do I contact Sanofi Ventures?

Public channels for Sanofi Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sanofi Ventures?

The team at Sanofi Ventures includes Christopher Gagliardi (Principal), Alan Walts (Managing Director) and Alba Zurriaga Carda (Director of Investments), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co